OncoMatch/Clinical Trials/NCT04376866
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
Is NCT04376866 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Toripalimab for recurrent nasopharyngeal carcinoma.
Treatment: Toripalimab — This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy alone in treating patients with locoregionally recurrent nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RT3-4N0-1M0, RT1-4N2-3M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
Neutrophil ≥ 1.5×10^9 /L and PLT ≥4×10^9 /L and HGB ≥90 g/L
Kidney function
creatinine clearance ≥60 ml/min
Liver function
ALT、AST ≤ 2.5×ULN, TBIL≤ 1.5×ULN
Neutrophil ≥ 1.5×10^9 /L and PLT ≥4×10^9 /L and HGB ≥90 g/L; With normal liver function test (ALT、AST ≤ 2.5×ULN, TBIL≤ 1.5×ULN); With normal renal function test ( creatinine clearance ≥60 ml/min)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04376866 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage RT3-4N0-1M0 or RT1-4N2-3M0 is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages